Arnold M. Baskies Buys 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIXGet Free Report) Director Arnold M. Baskies purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was purchased at an average price of $2.82 per share, with a total value of $14,100.00. Following the transaction, the director now owns 120,000 shares of the company’s stock, valued at approximately $338,400. This represents a 4.35 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Anixa Biosciences Trading Down 2.0 %

NASDAQ:ANIX opened at $2.94 on Friday. The firm has a market cap of $94.66 million, a price-to-earnings ratio of -7.54 and a beta of 0.90. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $4.70. The company’s 50-day moving average is $2.74 and its two-hundred day moving average is $3.05.

Anixa Biosciences (NASDAQ:ANIXGet Free Report) last announced its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. On average, equities research analysts forecast that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Anixa Biosciences during the 3rd quarter valued at about $34,000. Westside Investment Management Inc. increased its position in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management raised its stake in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the period. Finally, International Assets Investment Management LLC boosted its holdings in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after purchasing an additional 23,800 shares during the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on ANIX shares. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Get Our Latest Report on Anixa Biosciences

Anixa Biosciences Company Profile

(Get Free Report)

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.

Featured Stories

Insider Buying and Selling by Quarter for Anixa Biosciences (NASDAQ:ANIX)

Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.